#IOLChemicals #Q2Results #APIManufacturing #PharmaGrowth #EDQM #CEP #EBITDA #ProfitGrowth #SpecialtyChemicals
Chandigarh: IOL Chemicals and Pharmaceuticals Ltd (IOLCP) has announced robust standalone financial results for the second quarter (Q2) of FY26, reporting a significant surge in profitability driven by improved operating leverage and a strategic focus on its diverse product portfolio.
The company’s Profit After Tax (PAT) soared by 56.7% year-on-year (YoY) to ₹30.0 Crore in Q2 FY26, up from ₹19.2 Crore in Q2 FY25. This strong bottom-line growth was supported by a 33.3% YoY jump in EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) to ₹64.0 Crore.
📈 Financial Performance Snapshot (Q2 FY26)
| Particulars | Q2 FY26 (₹ Cr) | Q2 FY25 (₹ Cr) | Y-o-Y Change |
| Total Income | 567.5 | 525.8 | 7.9% |
| EBITDA | 64.0 | 48.0 | 33.3% |
| PAT | 30.0 | 19.2 | 56.7% |
| EBITDA Margin | 11.1% | 9.0% | +212 bps |
| PAT Margin | 5.2% | 3.6% | +162 bps |
Key Business & Operational Drivers
Joint Managing Director, Mr. Vikas Gupta, attributed the strong performance to continued operational strength and strategic focus. “EBITDA margin improved to 11.1% from 9.0%, driven by better operating leverage and cost efficiencies,” he commented. He noted that while YoY growth was strong, sequential PAT was marginally impacted by higher fuel costs due to temporary supply chain disruptions from the Punjab floods.
Segmental Growth: Both the Pharmaceuticals and Chemicals segments reported YoY EBIT growth. The Pharmaceuticals segment continues to gain momentum, led by strong traction in non-Ibuprofen APIs, signaling success in the company’s diversification strategy away from its core Ibuprofen product. The Chemicals segment is seeing steady volume recovery despite lingering pricing pressure.
Global Expansion: A major strategic highlight was the incorporation of IOLPharmaxis UK Limited in October 2025. This new subsidiary aims to strengthen international operations in the Pharmaceuticals and Chemicals business and expand the company’s global reach, improving customer proximity in key regions.
Regulatory Win: Further bolstering its international prospects, IOLCP secured the EDQM’s Certificate of Suitability (CEP) for its Pantoprazole Sodium Sesquihydrate Process-III on October 14, 2025. This critical certification enables the export of the Proton Pump Inhibitor (used to treat GERD and related conditions) to Europe and other CEP-compliant global markets.
IOL Chemicals has reaffirmed its focus on cost optimisation, process discipline, and maintaining a balanced product mix to sustain its momentum moving forward.
Hashtags:
#IOLChemicals #Q2Results #APIManufacturing #PharmaGrowth #EDQM #CEP #EBITDA #ProfitGrowth #SpecialtyChemicals
